Patents by Inventor Chi Wai Eric So

Chi Wai Eric So has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMBINATION OF AN INHIBITOR OF PARP WITH AN INHIBITOR OF GSK-3 OR DOT1L
    Publication number: 20210046072
    Abstract: Provided herein is a pharmaceutical combination comprising (a) a poly-(ADP-ribose)-polymerase (PARP) inhibitor and (b) a second agent comprising (i) an inhibitor of glycogen synthase kinase 3 (GSK-3) or (ii) an inhibitor of disrupter of telomeric silencing 1-like (DOT1L). Also provided is a method of treating a subject suffering from acute myeloid leukaemia, comprising administering to the subject a therapeutically effective amount of the pharmaceutical combination.
    Type: Application
    Filed: August 21, 2020
    Publication date: February 18, 2021
    Inventor: Chi Wai Eric So
  • Combination of an inhibitor of PARP with an inhibitor of GSK-3 or DOT1L
    Patent number: 10799501
    Abstract: Provided herein is a pharmaceutical combination comprising (a) a poly-(ADP-ribose)-polymerase (PARP) inhibitor and (b) a second agent comprising (i) an inhibitor of glycogen synthase kinase 3 (GSK-3) or (ii) an inhibitor of disrupter of telomeric silencing 1-like (DOT1L). Also provided is a method of treating a subject suffering from acute myeloid leukaemia, comprising administering to the subject a therapeutically effective amount of the pharmaceutical combination.
    Type: Grant
    Filed: November 4, 2016
    Date of Patent: October 13, 2020
    Assignee: King's College Hospital NHS Foundation Trust
    Inventor: Chi Wai Eric So
  • COMBINATION OF AN INHIBITOR OF PARP WITH AN INHIBITOR OF GSK-3 OR DOT1L
    Publication number: 20190076427
    Abstract: Provided herein is a pharmaceutical combination comprising (a) a poly-(ADP-ribose)-polymerase (PARP) inhibitor and (b) a second agent comprising (i) an inhibitor of glycogen synthase kinase 3 (GSK-3) or (ii) an inhibitor of disrupter of telomeric silencing 1-like (DOT1L). Also provided is a method of treating a subject suffering from acute myeloid leukaemia, comprising administering to the subject a therapeutically effective amount of the pharmaceutical combination.
    Type: Application
    Filed: November 4, 2016
    Publication date: March 14, 2019
    Inventor: Chi Wai Eric So
  • BIOMARKERS CORRELATED TO PARP INHIBITOR TREATMENT SUCCESS IN AML PATIENTS
    Publication number: 20160208339
    Abstract: In one aspect, there is provided a method for predicting responsiveness of a subject to a poly-(ADP-ribose)-polymerase (PARP) inhibitor for treating acute myeloid leukaemia (AML), the method comprising determining whether a chromosomal abnormality selected from t(8;21), t(15;17), t(16;16) and inv(16) is present in a sample obtained from the subject; wherein the presence of the chromosomal abnormality is indicative of responsiveness of the subject to the PARP inhibitor for treating AML.
    Type: Application
    Filed: September 17, 2014
    Publication date: July 21, 2016
    Inventors: Chi Wai Eric So, Maria Teresa Esposito